A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
ConditionAtopic Dermatitis (AD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChengdu Kangnuoxing Biopharma,Inc.
About this trial
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Trial participants aged 18 years or older at baseline, with no restrictions on gender.
Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Disqualifiers
Known history of allergic reaction to Stapokibart Injection.
Trial participants currently or plan participating in any interventional clinical trial.
Trial participants with hematologic malignancies.
Women with pregnant.
Trial population
Patients who are treated with Stapokibart Injection for AD at the physician's discretion (according to the China-specific prescribing information).
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Stapokibart
Biological/Vaccinesubcutaneous injection
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: Group of Stapokibart Injection1 intervention
Trial outcomes
Primary outcomes
1
The incidence rate of adverse reactions
Number of Adverse Reactions is calculated based on Adverse Events and Serious Adverse Events that were assessed by the investigator as related to the study drug and categorized according to the Medical Dictionary for Regulatory Activities.
Time frame
From enrollment to the end of treatment at 52 weeks.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov